Subtype
Cervical Neoplasm
CI-CAN-00004801Explore in graph →
Loading cancer entity…
Subtype
CI-CAN-00004801Explore in graph →
Variants & evidence
24 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AURKA Overexpression1 | ||||||||
| Paclitaxel | Cervical AdenocarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID457In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol. PMID 12559175 · Anand et al., 2003 · Open in CIViC | civic |
| BRCA1 W1815X1 | ||||||||
| Olaparib | Ovarian Endometrioid AdenocarcinomaALIAS | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID4623In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC) PMID 23415752 · Stordal et al., 2013 · Open in CIViC | civic |
| CD44 CD44v61 | ||||||||
| Cisplatin | Malignant Cervical Neoplasm | Predictive | B | Supports Resistance | 4 | submitted | EID9481In a clinical trial including 21 patients, CD44v6 expression (prior to and after to NAC) is a predictive factor of response to NAC by multivariate analysis (p = 0.0099 and p = 0.0470). Moreover, CD44v… (full text at CIViC) PMID 11136572 · Costa et al., 2001 · Open in CIViC | civic |
| NRG1 Fusion2 | ||||||||
| Afatinib | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7490A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC | civic |
| 〃 | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7494A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC) PMID 29169524 · Cheema et al., 2017 · Open in CIViC | civic |
| EGFR Amplification1 | ||||||||
| (prognostic) | Cervical Squamous Cell CarcinomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID471In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival. PMID 21730982 · Iida et al., 2011 · Open in CIViC | civic |
| NTRK3 Fusion1 | ||||||||
| (oncogenic) | Cervical Sarcoma | Oncogenic | C | Supports Oncogenicity | 1 | accepted | EID10483A 33-year-old Han Chinese woman has been associated with an NTRK fusion cervical sarcoma which was positive for Pan-TRK by immunohistochemistry (IHC) analysis. However, FISH for NTRK1 was negative. Th… (full text at CIViC) PMID 35572973 · Dang et al., 2022 · Open in CIViC | civic |
| ERBB2 Amplification1 | ||||||||
| Carboplatin + TrastuzumabCombination | Ovarian Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID13137Ovarian mucinous carcinoma responds poorly to paclitaxel and carboplatin, prompting interest in targeted therapy, and it resembles gastro-oesophageal adenocarcinoma, a tumour type in which HER2 (ERBB2… (full text at CIViC) PMID 20003286 · McAlpine et al., 2009 · Open in CIViC | civic |
| FGFR3 K508M1 | ||||||||
| (oncogenic) | Malignant Cervical Neoplasm | Oncogenic | D | Does Not Support Oncogenicity | 2 | submitted | EID11799A study that aims to analyse the biological significance of the FGFR3-TACC3 fusion. They transfected the K508M (also referred to as KD or kinase-dead) FGFR3-TACC3 fusion transcript into cervical epith… (full text at CIViC) PMID 29358619 · Tamura et al., 2018 · Open in CIViC | civic |
| TACC3 Fusion1 | ||||||||
| Fexagratinib | Cervical Squamous Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID9241Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC) PMID 32463741 · Chae et al., 2020 · Open in CIViC | civic |
| GNAS Mutation1 | ||||||||
| Palbociclib | Pseudomyxoma Peritonei | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID13146This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC) PMID 39413348 · Weitz et al., 2025 · Open in CIViC | civic |
| GNAS R2011 | ||||||||
| (prognostic) | Pseudomyxoma Peritonei | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1994Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC) PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC | civic |
| Type 181 | ||||||||
| (prognostic) | Malignant Cervical Neoplasm | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID12084Fresh tumor tissue 291 cervical cancer patients was fresh frozen at -70 degrees. DNA from samples was purified and analyzed via PCR for HPV 16, 18, and 6. HPV was found in 247 (85%) of tumors. HPV-16 … (full text at CIViC) PMID 8827013 · Burger et al., 1996 · Open in CIViC | civic |
| KRAS Mutation1 | ||||||||
| (prognostic) | Pseudomyxoma Peritonei | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID159640 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRA… (full text at CIViC) PMID 27502722 · Pietrantonio et al., 2016 · Open in CIViC | civic |
| KRAS Q22*1 | ||||||||
| Panitumumab | Colon Mucinous Adenocarcinoma | Predictive | C | Supports Resistance | 2 | accepted | EID1131A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC) PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC | civic |
| PIK3CA E545K3 | ||||||||
| Cisplatin | Malignant Cervical Neoplasm | Predictive | D | Supports Resistance | 3 | accepted | EID2985Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutat… (full text at CIViC) PMID 27489350 · Arjumand et al., 2016 · Open in CIViC | civic |
| Cisplatin + Ionizing RadiotherapySequential | Malignant Cervical Neoplasm | Predictive | D | Supports Resistance | 3 | accepted | EID8112Cervical cancer cell lines were treated with 1uM cisplatin followed by 1-6Gy ionizing radiation (IR). CaSki cells with PIK3CA E545K mutation show resistance to cisplatin plus IR when compared with HeL… (full text at CIViC) PMID 27489350 · Arjumand et al., 2016 · Open in CIViC | civic |
| Cisplatin + PictilisibCombination | Cervical Carcinoma | |||||||
| NRG1 Fusion2 | ||||||||
| Afatinib | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | rejected | EID7489A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC | civic |
| Erlotinib + LumretuzumabCombination | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID7495Two patients with EGFR/KRAS/ALK wild-type invasive mucinous adenocarcinoma of the lung were found to have SLC3A2-NRG1 fusions. Both patients were treated with combination lumretuzumab, an anti-HER3 mo… (full text at CIViC) PMID 30268483 · Kim et al., 2018 · Open in CIViC | civic |
| SPHK1 OVEREXPRESSION1 | ||||||||
| (prognostic) | Malignant Cervical Neoplasm | Prognostic | B | Supports Poor Outcome | 2 | accepted | EID830SPHK1 protein expression was assessed in 287 cervical cancer and 5 normal cervical tissue samples using IHC. Univariate analysis for OS showed SPHK1 expression (p = 0.033; Figure 1C), tumor size (p = … (full text at CIViC) PMID 26311741 · Kim et al., 2015 · Open in CIViC | civic |
| TP53 P72R1 | ||||||||
| (prognostic) | Malignant Cervical Neoplasm | Prognostic | B | Does Not Support Poor Outcome | 2 | accepted | EID1304In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds rat… (full text at CIViC) PMID 11535556 · Klug et al., 2001 · Open in CIViC | civic |
| TP53 R213*1 | ||||||||
| (predisposing) | Salivary Gland Mucinous Adenocarcinoma | Predisposing | E | Supports Pathogenic | 3 | submitted | EID7321As seen in Figure 1, the R213* mutation is predominantly found in colorectal and breast cancers. The variant was described as being a frequent p53 nonsense mutation in melanoma, kidney chromophobe, es… (full text at CIViC) PMID 28249646 · Panaccione et al., 2017 · Open in CIViC | civic |
| XRCC1 Q399R1 | ||||||||
| Carboplatin + CisplatinSubstitutes | Malignant Cervical Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID673The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (g… (full text at CIViC) PMID 16875718 · Chung et al., 2006 · Open in CIViC | civic |
Data updated 10 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| D |
| Supports Sensitivity Response |
| 3 |
| accepted |
EID2984CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly… (full text at CIViC) PMID 27489350 · Arjumand et al., 2016 · Open in CIViC |
| civic |